

FOR IMMEDIATE RELEASE
Website: <http://www.arthrt.com>

Contact: James E. Rouse
(978) 345-5000

June 29, 2010

Arrhythmia Research Technology, Inc. Announces Purchase of RMDDx Corporation

Fitchburg, MA

Arrhythmia Research Technology, Inc. ("ART" or the "Company") (NYSE AMEX: HRT) today announced that it completed the purchase of RMDDx Corporation ("RMDDx"), a Prince Edward Island development stage company, through the Company's newly formed U.S. subsidiary, RMDDxUSA Corp., as of June 18, 2010. ART issued an aggregate of 115,033 shares of its unregistered common stock and five year options to acquire an aggregate of 60,000 shares of common stock, exercisable at \$4.76 per share, in the transaction in exchange for the entirety of the outstanding shares and options of RMDDx. All of the shares of common stock were immediately placed in escrow and the stock and options are subject to release from escrow and vesting, respectively, only in the event certain performance and other targets are met.

Headquartered in the Atlantic Canada Province of Prince Edward Island, RMDDx was formed to develop and commercialize medical devices, medical information technology, medical diagnostics, and remote patient monitoring through advanced sensor, wireless, internet, and telecommunication technologies. RMDDx will develop and offer Mobile Cardiac Telemetry diagnostic monitoring services across the United States. RMDDx is also developing a premier monitoring platform to address multiple clinical indications for diagnostics and clinical trial support, as well as continuous or episodic long term care monitoring.

James Rouse, President and CEO of ART, commented, "The acquisition of RMDDx represents a strategic step into the medical device and service sectors to complement ART's SAECG software and our component manufacturing through our wholly-owned subsidiary, Micron Products, Inc. We believe that RMDDx will not only establish a place for ART in the medical device and diagnostic services market, but also provide a solid platform for further development and application of ART's software. This acquisition is an important step for us in our quest to build on our strong foundation as we seek to achieve sustained growth and increase stockholder value over the long term through diversification, product development and acquisition."

About Arrhythmia Research Technology, Inc.

The Company's products include proprietary signal-averaging electrocardiography (SAECG) software used in the detection of potentially lethal heart arrhythmias. The Company through its wholly owned subsidiary Micron Products, Inc. manufactures silver plated and non-silver plated conductive resin sensors and distributes metal snaps used in the manufacture of disposable ECG, EEG, EMS and TENS electrodes. Micron's MIT division provides end-to-end product life cycle management through a comprehensive portfolio of value-added services such as design, engineering, prototyping, manufacturing, machining, assembly and packaging. MIT manufactures custom injection molded products for medical, electronic, industrial and consumer applications, and provides high end mold design, manufacturing and precision machining for various industries.

For more information please visit our websites:

<http://www.arthrt.com>

<http://www.micronproducts.com>

<http://www.micronintegrated.com>

Forward Looking Statements

Forward-looking statements made herein are based on current expectations of the Company that involve a number of risks and uncertainties and should not be considered as guarantees of future performance. The factors that could cause actual results to differ materially include: our ability to maintain our current pricing model and/or decrease our cost of sales; continued availability of supplies or materials used in manufacturing at competitive prices; volatility in commodity and energy prices and our ability to offset higher costs with price increases; the costs inherent with complying with new statutes and regulations; variability of customer delivery requirements; our ability to efficiently integrate future acquisitions and other new lines of business that the Company may enter in the future. More information about factors that potentially could affect the Company's financial results is included in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2009.